Zyprexa Intramuscular, Olanzapine for Injection, 10 MG per Single Use Vial, Rx only, Marketed by: Lilly USA, LLC, Indianapolis, IN 46285, NDC# 0002-7597-01
Reason
cGMP deviations: Atypical appearance, decrease in size and change in color of the lyophilized cake of drug product.
Classification
Class II
Status
Terminated
Lot
Lot # 197
Date
Disclaimer: This tool indexes published US FDA drug-enforcement recall records from all countries, limited to the latest five years. A company or product not appearing here is not proof that it is compliant, approved, safe, or free of FDA action.
Eli Lilly & Company — Class II Recall | MedicineWatch US